Abbott Buys Solvay Pharma Unit But Is It Just A Short-Term Fix?
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott will buy the pharma business of its Belgian-based Tricor/TriLipix partner for $6.6 billion in cash; dependence on Humira, Tricor lingers.
You may also be interested in...
People In The News: Tracking The Latest Industry Personnel Moves
Presidents & CEOs
People In The News: Tracking The Latest Industry Personnel Moves
Presidents & CEOs
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings